Ariad Pharma: The Next HGSI? Print E-mail
Wednesday, 29 July 2009 09:02

For Ariad Pharmaceuticals (Nasdaq: ARIA), the past sessions have been exciting for shareholders.  Since Wednesday, July 24, 2009, shares have climbed 77% as of yesterday’s close.

 

 

Q3 CATALYST

An interim look at phase 3 data for ridaforolimus (rida), a promising new treatment for soft tissue and bone sarcoma, is due any day now.  If the phase 3 data are good, shares of ARIA will likely advance much higher from Tuesday’s close of $2.80.

 

Rida looks like a potential winner.  Check out Carolyn Boone's story and the results she achieved with rida.  Carolyn's story is summarized on pages 4 thru 7 of ARIA’s June 19, 2009 presentation.  Investors should find her story very compelling.  

 

WEBCAST JULY 30 4:15 PM

ARIA will host a webcast on Thursday, July 30, 2009 at 4:15 PM ET. Interested investors ought to make it a point to check it out. After the close on Thursday, access the webcast here.

 

UNIVERSAL CARE

Universal Care should fail to gain enough momentum to pass in the House of Representatives.  For this reason, the healthcare sector will continue to be in demand. Buy Biotech, namely Small-Cap, Late-Stage Drug Makers. 

 

Need ideas?  See this recent article on Lucky 13 Buys.

 

 

BOTTOM LINE

Keep your eye on ARIA.

 

 

Disclosure: Long ARIA and SPPI.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter